PRESENTATION #11 Clinical Research | Pain Medicine
EVALUATING CHRONIC USE OF OPIOIDS IN COVID-19 SURVIVORS
Yashar Eshraghi, MD, Ochsner Medical Center; Maged Guirguis, MD, Ochsner Medical Center;
Haider Ali, MD, Ochsner Medical Center; Madison Boudreaux, BS, UQ-Ochsner Clinical
School; Carmel Alemayehu, BS, Ochsner Medical Center
Presenter: Madison Boudreaux, BS UQ – Ochsner
Chronic opioid use, defined as use of opioids for three months or greater, is typically indicated for patients with chronic pain conditions. The United States opioid epidemic combined with the recent SARS-CoV-2 (COVID-19) pandemic has demonstrated a 32% rise in nonprescribed fentanyl use and 12.5% rise in heroin use per urine drug test analyses before and after the start of the pandemic (Wainwright et al). A subset of COVID-19 survivors given inpatient opioids are also being prescribed opioids at discharge. There is no existing literature on the development of chronic opioid use following admission for COVID-19. We plan to fill this gap. through this retrospective chart-review study.
Participants were chosen based on hospital admissions secondary to COVID-19 with inpatient opioid administration between March 1 and July 1, 2020. The cohort includes adult patients. Through chart reviews and utilization of Ochsner Health COVID-19 databases, the following patient data was collected: comorbidities, inpatient and outpatient opioid prescription data, follow-up visits, demographics, and social determinants of health. Patients were followed for 3 months post-discharge to identify if they met criteria of ‘chronic opioid use.’
Therapeutic opioids used in COVID-19 for myofascial pain must be weighed against the potential risk of abuse. Preliminary data suggests a smaller group of COVID-19 survivors requiring. hospitalization with opioid use later developed chronic opioid use, demonstrating low opioid dependence post-COVID-19.
Preliminary data analysis shows that fewer patients met criteria of ‘chronic opioid use’ compared to patients that did not. Further analysis will be conducted in order to determine which characteristics and significant comorbidities within this cohort demonstrate increased likelihood of developing chronic opioid use. We also plan to look at the types of prescription opioid medications used and utilization of telemedicine follow-up visits.